Inhibikase Therapeutics, Inc. (IKT) vs X4 Pharmaceuticals, Inc. (XFOR)
- Inhibikase Therapeutics, Inc. IKT 1.65 −9.84%
- X4 Pharmaceuticals, Inc. XFOR 2.59 −1.89%
Inhibikase Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and X4 Pharmaceuticals, Inc. are of similar size ($261.8M and $255.4M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −51.7%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −568.8%) and the higher return on invested capital (0.00% vs −226.6%). Across the 17 metrics below, Inhibikase Therapeutics, Inc. leads on 12 and X4 Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | IKT | XFOR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 81.51% | 65.16% |
| Operating margin | 0.00% | (554.71%) | 0.00% |
| Net margin | 0.00% | (568.80%) | 0.00% |
| Free cash flow margin | 0.00% | (559.95%) | 0.00% |
| Return on equity | (51.96%) | (113.08%) | (56.36%) |
| Return on assets | (48.04%) | (50.32%) | (48.04%) |
| Return on invested capital | 0.00% | (226.62%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack